Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 3901–3950 of 18397
Tim Wan tendered to the Board of Directors (the “Board”) of Asana, Inc. (the “Company”) his resignation as Chief Financial Officer of the Company, effective as of September 10, 2024.
Mr. Jolley will continue as an employee of the Company, serving as senior adviser, finance, effective November 1, 2024.
appointed Tod Crane as the Company's chief financial officer, effective November 1, 2024.
On September 1, 2024, Jason O’Byrne, the Chief Financial Officer of Caribou Biosciences, Inc. (the “Company”), informed the Company of his intent to resign from his position, effective September 27, 2024, to pursue another opportunity.
On September 3, 2024, the Company announced the appointment of Ashley Cordova, age 45, who is currently serving as the Company’s Chief Financial Officer, as the Chief Executive Officer of the Company and its respective direct and indirect subsidiaries and affiliates (together, the “Novocure Group”), effective January 1, 2025.
On August 29, 2024, C. Timothy Trenary, 68, Executive Vice President, Chief Financial Officer of Superior Industries International, Inc. (the “Company” or “Superior”), notified the Company of his intent to retire from his position at Superior effective September 30, 2024.
Dan Lee, Superior’s Vice President of Finance and CFO Europe, has been appointed to serve as the Company’s Senior Vice President, Chief Financial Officer beginning on October 1, 2024.
Mark Austin ceased serving as an executive officer of the Company and as the Company's “co-principal financial officer” and “principal accounting officer” on August 16, 2024.
On August 27, 2024, Brian Piekos, the Chief Financial Officer and Treasurer of Elicio Therapeutics, Inc. (the “Company”), informed the Company of his intent to resign from his positions, effective September 6, 2024, to pursue another opportunity.
appointed Roy M. Gonzales, the Company’s Senior Vice President of Finance, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of August 30, 2024
Dr. Auster ceased employment as the Company’s Chief Financial Officer, effective as of August 30, 2024.
Joseph A. Mills, a member of the Company’s Board of Directors (the “Board”), will serve as Interim Chief Executive Officer and President, effective as of August 29, 2024.
Timothy S. Duncan departed his role as President and Chief Executive Officer of the Company, effective as of August 29, 2024.
In addition, Amit Kumar Garg resigned as Chief Financial Officer of the Company as of the Effective Date.
Blink Charging Co. (the “Company”) is reporting that Brendan Jones, the Company’s President and Chief Executive Officer, informed the Board of Directors of the Company (the “Board”) on August 27, 2024, that he will step down from his role as the Company’s President and Chief Executive Officer and will retire from the Company effective January 31, 2025.
The Company is also reporting that the Board has appointed Michael Battaglia to serve as the successor to Mr. Jones as the Company’s President and Chief Executive Officer effective February 1, 2025.
Effective August 30, 2024, the board of directors (the “Board”) of OneMedNet Corporation (the “Company”) appointed Robert Golden to serve as Chief Financial Officer (“CFO”) on an interim basis.
Effective August 30, 2024, Lisa Embree departed as the Company’s CFO, Executive Vice President, Treasurer and Secretary.
appointed Peter Tassiopoulos to serve as our Chief Executive Officer, effective September 16, 2024
In Ms. Strong’s absence, Richard Dziadzio, the Company’s Executive Vice President, Interim Chief Financial Officer, will assume Ms. Strong’s duties as the Company’s principal accounting officer and serve as the Company’s Executive Vice President, Interim Chief Financial Officer and Interim Chief Accounting Officer.
The Board of the Company appointed Wang Wen Lung (age 59) as the Chief Executive Officer, Chief Financial Officer, effective on August 28, 2024.
The Board of the Company appointed Wang Wen Lung (age 59) as the Chief Executive Officer, Chief Financial Officer, effective on August 28, 2024.
effective August 28, 2024, Zhenlong Zhao was appointed as Chief Executive Officer, Chief Financial Officer, Secretary and sole Director.
On August 29, 2024, Tyson Foods, Inc. (the “Company”) appointed Curt Calaway as the Company’s Chief Financial Officer.
On August 28, 2024, the Company appointed Ryan D. Lake as the Company’s Chief Financial Officer and Secretary, effective September 3, 2024
Mr. Morberg's separation will be treated as a termination by the Company without Cause subsequent to a Change in Control under that certain Executive Employment Agreement (the "Morberg Employment Agreement"), dated January 19, 2021, between the Company and Mr. Morberg
On August 23, 2024, the Board of Directors (the “Board”) of Universal Corporation (the “Company”) named Preston D. Wigner, Senior Vice President, as Chairman of the Board (“Chairman”), President and Chief Executive Officer of the Company, effective October 1, 2024.
George C. Freeman, III, who notified the Board of his retirement as Chairman, President and Chief Executive Officer and as a member of the Board on August 23, 2024, with such retirement effective October 1, 2024.
Mr. Brian Di Donato notified Immunocore Holdings plc (the “Company”) of his decision to resign as Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer of the Company, effective December 31, 2024, to pursue another opportunity.
On August 26, 2024, Michael Mason notified Karyopharm Therapeutics Inc. (the “Company”) of his intention to resign as the Company’s Executive Vice President, Chief Financial Officer and Treasurer to pursue other professional interests.
James Langrock has been appointed Chief Financial Officer of the Company.
William E. Shea will retire from his position as Senior Vice President, Treasurer and Chief Financial Officer.
On August 27, 2024 the Board of Directors of Selectis Health, Inc., a Utah corporation (the “Company”) approved the appointment of James Creamer to the position of Chief Financial Officer, effective August 15, 2024.
On August 29, 2024, the Board of Directors (the “Board”) of P3 Health Partners Inc. (the “Company”) appointed Leif Pedersen as Chief Financial Officer of the Company, effective as of October 1, 2024 (the “Effective Date”).
Mr. Pedersen will succeed Atul Kavthekar, who resigned from his position as Chief Financial Officer of the Company effective as of the Effective Date.
Jill Robinson, age 54, has been appointed Executive Vice President, Chief Financial Officer and Treasurer of the Company.
Terence F. McGuirk, age 73, has been appointed to the role of President and Chief Executive Officer of the Company.
On August 22, 2024, Michael J. Berry informed the Company of his decision to transition from his role of Executive Vice President and Chief Financial Officer by May 23, 2025.
Ms. Kowalchik will replace David Rawden, who has served as Interim Chief Financial Officer since July 12, 2024.
On August 28, 2024, Methode Electronics, Inc. (the “Company”) announced the appointment of Laura Kowalchik as the Company’s Chief Financial Officer, effective October 1, 2024.
Chipotle’s Board of Directors appointed Scott Boatwright as Interim Chief Executive Officer
advanced the date of Mr. Rymer’s appointment as Chief Financial Officer
the Company issued a press release announcing Mr. Cook’s resignation.
On August 28, 2024, the Company announced that Amy Weaver will step down from her role as President and Chief Financial Officer of the Company effective upon the appointment of her successor or upon the filing of the Company’s annual report on Form 10-K for the fiscal year ending January 31, 2025 (the “10-K Filing Date”), if earlier.
On August 28, 2024 (the “Effective Date”), BJ’s Restaurants, Inc. (the “Company”) announced that its Board of Directors (the “Board”) approved the appointment of C. Bradford Richmond as Interim Chief Executive Officer of the Company.
On August 28, 2024, the Company announced that effective as of August 28, 2024, Gregory S. Levin would no longer serve as the Company’s Chief Executive Officer and President or as a member of the Board.
On August 23, 2024, Garrett L. Chase agreed to join Viasat, Inc. (“Viasat”) in the role of Senior Vice President and Chief Financial Officer, effective September 16, 2024.
On August 21, 2024, the board of directors (the “Board”) of IR-Med, Inc. (the “Company”) appointed Mr. Ran Ziskind to serve as its Chief Executive Officer (CEO), replacing Mr. Ronnie Klein, who had been serving as Interim CEO, effective September 1, 2024.
John Hartmann no longer serves as Chief Executive Officer of the Company.
the Board appointed Samuel Brill as Chief Executive Officer of the Company and removed him as Lead Independent Director of the Board, while maintaining his appointment as director of the Company, effective immediately.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.